Recent developments highlight IM Cannabis Corp.'s strategic initiatives including capital raises, acquisitions, and market expansion efforts amid regulatory challenges.

• IM Cannabis raised approximately US$2.17 million through note purchase agreements in January 2026 to support debt repayment and general corporate purposes [N2][S2].
• The company is pursuing expansion into the U.S. market following regulatory changes, as reported in December 2025 [N3].
• IM Cannabis signed a term sheet to acquire a 60% stake in Quantum Bio Data Firm in October 2025, indicating diversification efforts [N4].
• The company faces global challenges and awaits regulatory reforms impacting its markets as of March 2026 [N1].

IM Cannabis benefits from its established presence in the growing medical cannabis markets of Israel and Germany, supported by licensed retail pharmacies and a certified logistics center. Strategic acquisitions, such as full ownership of Focus Medical Herbs Ltd., and partnerships with premium Canadian brands enhance its product offerings. The company's recent capital raises provide liquidity to support operations and potential expansion. Regulatory reforms in Germany and potential U.S. market entry offer avenues for business growth. Operational efficiencies implemented in Israel and Germany may improve profitability over time.

The company reported a net loss and liquidity ratios below 1.0 as of December 31, 2025, indicating financial strain and potential challenges in meeting short-term obligations. The medical cannabis markets in Israel and Germany are subject to complex and evolving regulations, including an ongoing anti-dumping investigation in Israel that could increase costs. The company faces competitive pressures and geopolitical risks affecting supply chains and operations. Its cessation of Canadian operations and reliance on capital raises highlight financial and operational risks. Expansion into new markets such as the U.S. involves regulatory and execution uncertainties.

IM Cannabis Corp.'s moat is supported by its licensed operations in regulated medical cannabis markets in Israel and Germany, including ownership of licensed pharmacies and a certified logistics and processing facility in Germany. Its strategic alliances with Canadian suppliers and proprietary genetics through third-party cultivation provide product sourcing advantages. The company's EU-GMP certifications and exclusive licensing agreements for premium brands in Germany enhance its market positioning. However, the company operates in highly regulated and evolving markets with competitive pressures and regulatory risks, which may limit moat durability.

• Regulatory Risks: IM Cannabis operates in highly regulated markets in Israel and Germany, facing risks from changing cannabis laws, licensing requirements, and investigations such as the Israeli anti-dumping probe that could increase costs and impact operations.
• Financial and Liquidity Risks: The company reported a net loss and current liabilities exceeding current assets as of December 31, 2025, indicating liquidity constraints. Dependence on credit facilities and capital raises to fund operations presents financial risk.
• Market and Competitive Risks: The medical cannabis industry is competitive with evolving patient demand and pricing pressures. The company must maintain licenses and supplier relationships to sustain its market position.
• Operational Risks: Geopolitical events and logistical disruptions have impacted operations, requiring adjustments in supply chain and workforce. Expansion into new markets such as the U.S. carries execution risks.

• IM Cannabis Corp. is an international cannabis company focused on importation, distribution, and sale of medical cannabis products primarily in Israel and Germany [S1].
• The company operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel through its subsidiaries [S1].
• IM Cannabis holds two licensed pharmacies in Israel: Vironna (serving the Arab consumer segment) and Pharm Yarok (a large pharmacy with a call center for deliveries) [S1].
• In Germany, operations are conducted through its subsidiary Adjupharm, which holds EU-GMP licenses for repackaging, stability testing, and batch release activities [S1].
• Adjupharm sources medical cannabis from EU-GMP certified suppliers and holds wholesale, narcotics handling, manufacturing, procurement, storage, distribution, and import/export licenses [S1].
• The company completed a 6-for-1 share consolidation in July 2024 to regain Nasdaq compliance [S1].
• IM Cannabis acquired 100% ownership of Focus Medical Herbs Ltd. by May 2025, making it a wholly owned subsidiary [S1].
• The company ceased material Canadian operations following restructuring proceedings that ended in September 2023, focusing on Israel and Germany [S1].
• Financial snapshot as of December 31, 2025: revenue of CAD 54.7 million, net loss of CAD 11.75 million, cash and equivalents of CAD 2.73 million, current assets of CAD 22.74 million, current liabilities of CAD 34.01 million, current ratio 0.67, and cash ratio 0.08 [S1].
• The company is classified as an emerging growth company under U.S. securities laws and benefits from certain reporting exemptions [S1].
• IM Cannabis raised approximately US$2.17 million through note purchase agreements in January 2026, with proceeds intended for debt repayment and general corporate purposes [N2][S2].
• The company is pursuing expansion into the U.S. market following regulatory changes, as reported in December 2025 [N3].
• IM Cannabis signed a term sheet to acquire a 60% stake in Quantum Bio Data Firm in October 2025 [N4].
• The company faces global challenges and awaits regulatory reforms impacting its markets as of March 2026 [N1].
• IM Cannabis leverages strategic alliances with Canadian suppliers and third-party cultivation facilities in Israel to supply medical cannabis products [S1].
• The German Logistics Center owned by Adjupharm manages supply chain, production, repackaging, and distribution of bulk medical cannabis [S1].
• The company has credit facilities with Israeli financial institutions, with outstanding borrowings of approximately CAD 2 million as of December 31, 2025 [S1].
• IM Cannabis operates under complex regulatory environments in Israel and Germany, including licensing requirements and ongoing investigations such as an anti-dumping probe in Israel [S1][N1].